UiPath Inc. (NASDAQ:PATH – Get Rating) Director Kimberly Hammonds sold 2,521 shares of the stock in a transaction that occurred on Tuesday, June 21st. The shares were sold at an average price of $18.70, for a total transaction of $47,142.70. Following the sale, the director now directly owns 100,662 shares of the company’s stock, valued at approximately $1,882,379.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of PATH stock traded up $0.81 during trading hours on Tuesday, reaching $19.26. The company had a trading volume of 6,381,315 shares, compared to its average volume of 6,711,852. The stock has a fifty day moving average of $18.06 and a 200-day moving average of $28.98. The company has a market capitalization of $10.49 billion, a price-to-earnings ratio of -25.01 and a beta of 0.33. UiPath Inc. has a 12-month low of $13.66 and a 12-month high of $72.90.
UiPath (NASDAQ:PATH – Get Rating) last issued its quarterly earnings data on Wednesday, June 1st. The healthcare company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.03. The company had revenue of $245.07 million during the quarter, compared to analyst estimates of $225.37 million. UiPath had a negative return on equity of 18.47% and a negative net margin of 42.95%. The firm’s revenue for the quarter was up 31.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.81) earnings per share. As a group, analysts anticipate that UiPath Inc. will post -0.59 earnings per share for the current fiscal year.
Institutional investors have recently modified their holdings of the stock. Baldwin Brothers LLC MA purchased a new position in UiPath in the fourth quarter worth approximately $26,000. Sterling Investment Advisors Ltd. purchased a new position in UiPath in the fourth quarter worth approximately $30,000. CarsonAllaria Wealth Management Ltd. purchased a new position in UiPath in the fourth quarter worth approximately $30,000. Benjamin Edwards Inc. grew its position in UiPath by 65.4% in the fourth quarter. Benjamin Edwards Inc. now owns 708 shares of the healthcare company’s stock worth $31,000 after acquiring an additional 280 shares during the period. Finally, Emerald Mutual Fund Advisers Trust purchased a new position in UiPath in the fourth quarter worth approximately $40,000. Institutional investors own 52.19% of the company’s stock.
A number of equities research analysts recently commented on the stock. KeyCorp decreased their target price on shares of UiPath from $34.00 to $23.00 and set an “overweight” rating for the company in a research report on Monday, April 25th. Morgan Stanley decreased their target price on shares of UiPath from $74.00 to $41.00 and set an “overweight” rating for the company in a research report on Thursday, March 31st. BMO Capital Markets decreased their target price on shares of UiPath from $29.00 to $21.00 in a research report on Thursday, June 2nd. Canaccord Genuity Group decreased their target price on shares of UiPath from $55.00 to $30.00 in a research report on Thursday, March 31st. Finally, Royal Bank of Canada decreased their target price on shares of UiPath from $32.00 to $27.00 in a research report on Tuesday, May 31st. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $36.70.
UiPath Company Profile (Get Rating)
UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.